Systemic inflammation can be ameliorated by administration of IL-6-neutralizing antibodies that are clinically validated in the management of immune-mediated adverse events, developing after cancer immunotherapies with checkpoint inhibitors or adoptive treatment with chimeric antigen receptor (CAR) T cells [39, 40]. The gene discussed is IL6; the disease is cancer.